Jennifer C Boldrick, MD
Dermatology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 16
- 2 carriers
- Offices
- 5
Offices
5 locations · Stanford Health Care · Sutter Bay Medical Foundation
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
16 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Boldrick’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
16 of 16 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A88543 · Current
Licensed to practise in California · since 2004 · expires 2028-02-29 · Stanford University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$158,114
Medicare paid this office $158,114 for 547 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Short return visit (20+ min) | 440 | $57,826 | $76 |
| Destruction of skin growth, 1-14 growths | 243 | $38,873 | $109 |
| Destruction of precancer skin growth, 1 growth | 204 | $18,258 | $52 |
| Return visit (30+ min) | 87 | $11,659 | $112 |
| Biopsy of related skin growth, first growth | 103 | $10,655 | $87 |
See all 10 services
| Short return visit (20+ min) | 440 | $57,826 | $76 |
| Destruction of skin growth, 1-14 growths | 243 | $38,873 | $109 |
| Destruction of precancer skin growth, 1 growth | 204 | $18,258 | $52 |
| Return visit (30+ min) | 87 | $11,659 | $112 |
| Biopsy of related skin growth, first growth | 103 | $10,655 | $87 |
| Destruction of precancer skin growth, 2-14 growths | 165 | $7,675 | $7 |
| Return visit (30+ min) | 17 | $2,107 | $81 |
| Short return visit | 28 | $1,742 | $48 |
| New patient visit (30+ min) | 13 | $1,280 | $98 |
| New patient visit (15+ min) | 22 | $1,256 | $57 |
Procedures Medicare counted
| Removal of skin lesions | 1057 | More than 94% of doctors who do this |
| Skin biopsy | 145 | More than 80% of doctors who do this |
Who their Medicare patients are
547 Original Medicare patients in 2024. Average age 75 · Women 64% · Also on Medicaid 3% · Health risk score 0.84. At or below the middle of the specialty; the typical dermatology clinician is at 1.01.
Conditions among them: High blood pressure 56% · Cancer 18% · Coronary heart disease 17% · Diabetes 14% · Atrial fibrillation 14% · Chronic kidney disease 11% · Depression 9% · Heart failure 5% · COPD 4% · Stroke 3% · Dementia 2%.
The office billed $530,306, Medicare allowed $219,540 and paid $158,114; for 3,078 services of 25 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 547 | 3,078 | 75 | 0.84 | $530,306 | $158,114 |
| 2023 | 514 | 2,892 | 75 | 0.78 | $476,903 | $143,921 |
| 2022 | 499 | 2,589 | 75 | 0.80 | $436,431 | $133,088 |
| 2021 | 498 | 2,593 | 74 | 0.71 | $415,395 | $126,427 |
| 2020 | 457 | 2,168 | 74 | 0.80 | $342,950 | $98,752 |
| 2019 | 505 | 2,834 | 74 | 0.82 | $442,221 | $126,864 |
| 2018 | 440 | 2,618 | 74 | 0.81 | $398,081 | $107,284 |
| 2017 | 439 | 2,338 | 74 | 0.79 | $341,418 | $102,070 |
| 2016 | 411 | 2,083 | 74 | 0.82 | $294,742 | $86,658 |
| 2015 | 414 | 1,788 | 74 | 0.81 | $286,343 | $90,101 |
| 2014 | 349 | 1,411 | 74 | 0.83 | $216,986 | $67,482 |
| 2013 | 328 | 1,233 | 73 | 0.79 | $211,489 | $61,762 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 10 services
| Short return visit (20+ min) | 412 | $49,579 | $73 |
| Destruction of skin growth, 1-14 growths | 205 | $33,558 | $110 |
| Destruction of precancer skin growth, 1 growth | 202 | $17,877 | $54 |
| Biopsy of related skin growth, first growth | 104 | $11,063 | $86 |
| Return visit (30+ min) | 76 | $8,595 | $100 |
| Destruction of precancer skin growth, 2-14 growths | 164 | $7,134 | $7 |
| Short return visit | 42 | $2,284 | $49 |
| New patient visit (15+ min) | 30 | $1,715 | $57 |
| Return visit (30+ min) | 13 | $1,536 | $90 |
| Biopsy of related skin growth, each additional growth | 18 | $1,160 | $48 |
2022: 12 services
| Short return visit (20+ min) | 407 | $45,865 | $71 |
| Destruction of skin growth, 1-14 growths | 214 | $33,078 | $101 |
| Destruction of precancer skin growth, 1 growth | 181 | $14,716 | $51 |
| Return visit (30+ min) | 58 | $8,911 | $106 |
| Biopsy of related skin growth, first growth | 79 | $8,067 | $86 |
| Destruction of precancer skin growth, 2-14 growths | 147 | $5,836 | $7 |
| Application of light to destroy precancer skin growth | 11 | $1,611 | $146 |
| New patient visit (15+ min) | 26 | $1,500 | $58 |
| Return visit (30+ min) | 13 | $1,438 | $85 |
| Short return visit | 22 | $1,421 | $44 |
| New patient visit (30+ min) | 15 | $1,285 | $86 |
| Biopsy of related skin growth, each additional growth | 11 | $631 | $53 |
2021: 13 services
| Short return visit (20+ min) | 389 | $43,294 | $71 |
| Destruction of skin growth, 1-14 growths | 185 | $28,177 | $106 |
| Destruction of precancer skin growth, 1 growth | 181 | $13,929 | $48 |
| Biopsy of related skin growth, first growth | 99 | $9,614 | $85 |
| Return visit (30+ min) | 64 | $9,174 | $94 |
| Destruction of precancer skin growth, 2-14 growths | 142 | $5,843 | $7 |
| New patient visit (15+ min) | 45 | $2,142 | $48 |
| New patient visit (30+ min) | 19 | $1,748 | $92 |
| Return visit (30+ min) | 12 | $1,449 | $76 |
| Short return visit | 28 | $1,428 | $43 |
| Influenza vaccine split virus, preservative free | 14 | $914 | $65 |
| Biopsy of related skin growth, each additional growth | 14 | $763 | $54 |
| Administration of influenza virus vaccine | 15 | $317 | $21 |
2020: 13 services
| Short return visit (20+ min) | 325 | $27,310 | $58 |
| Destruction of skin growth, 1-14 growths | 175 | $24,512 | $103 |
| Destruction of precancer skin growth, 1 growth | 138 | $10,938 | $49 |
| Biopsy of related skin growth, first growth | 89 | $8,275 | $83 |
| Return visit (30+ min) | 56 | $7,662 | $85 |
| Destruction of precancer skin growth, 2-14 growths | 115 | $4,311 | $6 |
| New patient visit (15+ min) | 56 | $3,077 | $55 |
| New patient visit (30+ min) | 15 | $1,492 | $99 |
| Short return visit | 31 | $1,309 | $36 |
| Return visit (30+ min) | 12 | $1,094 | $64 |
| Influenza vaccine split virus, preservative free | 13 | $793 | $61 |
| Biopsy of related skin growth, each additional growth | 11 | $565 | $51 |
| Administration of influenza virus vaccine | 13 | $268 | $21 |
2019: 10 services
| Short return visit (20+ min) | 387 | $37,758 | $61 |
| Destruction of skin growth, 1-14 growths | 202 | $30,342 | $106 |
| Destruction of precancer skin growth, 1 growth | 170 | $15,068 | $49 |
| Return visit (30+ min) | 60 | $9,058 | $84 |
| Biopsy of related skin growth, first growth | 100 | $9,032 | $79 |
| Destruction of precancer skin growth, 2-14 growths | 135 | $4,446 | $5 |
| New patient visit (15+ min) | 47 | $2,783 | $59 |
| Short return visit | 42 | $1,968 | $38 |
| Return visit (30+ min) | 13 | $1,364 | $62 |
| Biopsy of related skin growth, each additional growth | 17 | $1,018 | $54 |
2018: 10 services
| Short return visit (20+ min) | 333 | $30,395 | $56 |
| Destruction of skin growth, 1-14 growths | 145 | $18,590 | $98 |
| Destruction of precancer skin growth, 1 growth | 179 | $13,780 | $48 |
| Biopsy of single growth of skin and/or tissue | 95 | $9,912 | $86 |
| Return visit (30+ min) | 50 | $7,014 | $85 |
| Destruction of precancer skin growth, 2-14 growths | 151 | $4,291 | $5 |
| New patient visit (15+ min) | 43 | $2,582 | $60 |
| Short return visit | 48 | $1,859 | $33 |
| Return visit (30+ min) | 16 | $1,413 | $71 |
| Biopsy of each additional growth of skin and/or tissue | 17 | $638 | $30 |
2017: 10 services
| Short return visit (20+ min) | 316 | $28,773 | $57 |
| Destruction of skin growth, 1-14 growths | 171 | $23,726 | $101 |
| Destruction of precancer skin growth, 1 growth | 142 | $11,735 | $50 |
| Biopsy of single growth of skin and/or tissue | 88 | $8,373 | $84 |
| Return visit (30+ min) | 44 | $5,908 | $87 |
| Destruction of precancer skin growth, 2-14 growths | 112 | $4,557 | $5 |
| New patient visit (15+ min) | 58 | $2,995 | $52 |
| Short return visit | 34 | $1,582 | $36 |
| New patient visit (30+ min) | 17 | $1,373 | $81 |
| Biopsy of each additional growth of skin and/or tissue | 14 | $551 | $31 |
2016: 11 services
| Short return visit (20+ min) | 289 | $24,593 | $58 |
| Destruction of skin growth, 1-14 growths | 143 | $20,810 | $108 |
| Destruction of precancer skin growth, 1 growth | 145 | $11,026 | $51 |
| Biopsy of single growth of skin and/or tissue | 81 | $7,842 | $87 |
| Destruction of precancer skin growth, 2-14 growths | 120 | $4,350 | $6 |
| New patient visit (15+ min) | 69 | $4,071 | $59 |
| Return visit (30+ min) | 31 | $3,653 | $94 |
| Short return visit | 32 | $1,395 | $36 |
| New patient visit (30+ min) | 14 | $1,187 | $85 |
| Return visit (30+ min) | 11 | $1,051 | $66 |
| Biopsy of each additional growth of skin and/or tissue | 11 | $401 | $31 |
2015: 11 services
| Short return visit (20+ min) | 269 | $23,778 | $61 |
| Destruction of skin growth, 1-14 growths | 157 | $22,699 | $112 |
| Destruction of precancer skin growth, 1 growth | 133 | $9,208 | $51 |
| Biopsy of single growth of skin and/or tissue | 81 | $8,196 | $91 |
| New patient visit (15+ min) | 91 | $5,461 | $60 |
| Destruction of precancer skin growth, 2-14 growths | 110 | $3,228 | $6 |
| Return visit (30+ min) | 23 | $2,866 | $87 |
| Short return visit | 33 | $1,542 | $41 |
| Return visit (30+ min) | 12 | $1,122 | $66 |
| New patient visit (30+ min) | 16 | $1,098 | $69 |
| Removal of skin tag, 1-15 skin tags | 11 | $855 | $78 |
2014: 10 services
| Short return visit (20+ min) | 238 | $18,640 | $55 |
| Destruction of skin growth, 1-14 growths | 115 | $14,064 | $101 |
| Destruction of precancer skin growth, 1 growth | 103 | $8,199 | $57 |
| Biopsy of single growth of skin and/or tissue | 67 | $6,456 | $90 |
| Destruction of precancer skin growth, 2-14 growths | 88 | $4,931 | $10 |
| New patient visit (15+ min) | 87 | $4,859 | $56 |
| Return visit (30+ min) | 13 | $1,837 | $87 |
| New patient visit (30+ min) | 11 | $1,063 | $97 |
| Return visit (30+ min) | 11 | $839 | $70 |
| Short return visit | 17 | $627 | $33 |
2013: 7 services
| Short return visit (20+ min) | 221 | $17,680 | $56 |
| Destruction of skin growth, 1-14 growths | 93 | $12,054 | $106 |
| Destruction of precancer skin growth, 1 growth | 96 | $8,342 | $64 |
| Biopsy of single growth of skin and/or tissue | 74 | $7,753 | $89 |
| New patient visit (15+ min) | 93 | $5,263 | $57 |
| Destruction of precancer skin growth, 2-14 growths | 79 | $2,538 | $6 |
| Short return visit | 18 | $686 | $33 |
Drugs they prescribed that Part D paid
$272,369
Pharmacies billed $272,369 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 871) in 2024. At or below the middle of the specialty; the typical dermatology clinician is at 0%.
811 generic and 60 brand-name prescriptions · $272,369 in drug cost · 69 antibiotic prescriptions to 16 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Cosentyx Sensoready (2 Pens) | 13 | $92,420 | $7,109 |
| Otezla | 12 | $54,406 | $4,534 |
| Dupixent | 14 | $52,517 | $3,751 |
| Fluorouracil | 48 | $3,258 | $68 |
| Clobetasol Propionate | 42 | $2,697 | $64 |
See all 25 drugs
| Cosentyx Sensoready (2 Pens) | 13 | $92,420 | $7,109 |
| Otezla | 12 | $54,406 | $4,534 |
| Dupixent | 14 | $52,517 | $3,751 |
| Fluorouracil | 48 | $3,258 | $68 |
| Clobetasol Propionate | 42 | $2,697 | $64 |
| Tretinoin | 17 | $1,822 | $107 |
| Fluocinonide | 47 | $1,541 | $33 |
| Clindamycin Phosphate | 42 | $1,360 | $32 |
| Tacrolimus | 11 | $1,118 | $102 |
| Metronidazole | 27 | $1,089 | $40 |
| Doxycycline Hyclate | 23 | $1,068 | $46 |
| Ciclopirox | 61 | $904 | $15 |
| Triamcinolone Acetonide | 79 | $871 | $11 |
| Betamethasone Diprop Augmented | 25 | $762 | $30 |
| Desonide | 14 | $610 | $44 |
| Minoxidil | 52 | $541 | $10 |
| Ciclopirox | 13 | $485 | $37 |
| Hydroxychloroquine Sulfate | 15 | $409 | $27 |
| Ketoconazole | 24 | $391 | $16 |
| Mometasone Furoate | 22 | $317 | $14 |
| Valacyclovir | 25 | $298 | $12 |
| Hydrocortisone | 47 | $256 | $5 |
| Sulfamethoxazole-Trimethoprim | 17 | $200 | $12 |
| Cephalexin | 12 | $115 | $10 |
| Mupirocin | 13 | $100 | $8 |
Year by year
| 2024 | 871 | 270 | 0% (0) | 7% | $272,369 |
| 2023 | 794 | 249 | None | 5% | $175,822 |
| 2022 | 776 | 242 | None | 7% | $240,780 |
| 2021 | 640 | 237 | 0% (0) | 10% | $185,317 |
| 2020 | 662 | 230 | 0% (0) | 11% | $150,383 |
| 2019 | 608 | 227 | 0% (0) | 10% | $139,479 |
| 2018 | 536 | 197 | 0% (0) | 16% | $149,512 |
| 2017 | 379 | 170 | 0% (0) | 17% | $122,670 |
| 2016 | 327 | 142 | None | 17% | $131,276 |
| 2015 | 283 | 130 | 0% (0) | 22% | $87,291 |
| 2014 | 219 | 123 | 0% (0) | None | $20,138 |
| 2013 | 249 | 135 | 0% (0) | 28% | $19,562 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 25 drugs
| Cosentyx Sensoready (2 Pens) | 13 | $104,025 | $8,002 |
| Fluorouracil | 51 | $4,715 | $92 |
| Tretinoin | 15 | $2,404 | $160 |
| Fluocinonide | 58 | $2,159 | $37 |
| Metronidazole | 23 | $1,939 | $84 |
| Clobetasol Propionate | 36 | $1,843 | $51 |
| Clindamycin Phosphate | 36 | $1,763 | $49 |
| Triamcinolone Acetonide | 89 | $1,417 | $16 |
| Nyamyc | 12 | $1,182 | $99 |
| Ciclopirox | 67 | $1,166 | $17 |
| Doxycycline Hyclate | 24 | $719 | $30 |
| Betamethasone Diprop Augmented | 19 | $676 | $36 |
| Sulfamethoxazole-Trimethoprim | 17 | $498 | $29 |
| Ciclopirox | 14 | $486 | $35 |
| Valacyclovir | 25 | $419 | $17 |
| Alclometasone Dipropionate | 19 | $360 | $19 |
| Cephalexin | 13 | $347 | $27 |
| Hydrocortisone | 47 | $284 | $6 |
| Doxycycline Monohydrate | 11 | $260 | $24 |
| Mometasone Furoate | 20 | $227 | $11 |
| Gabapentin | 13 | $199 | $15 |
| Ketoconazole | 15 | $196 | $13 |
| Minoxidil | 18 | $137 | $8 |
| Mupirocin | 15 | $96 | $6 |
| Ibuprofen | 15 | $38 | $3 |
2022: 21 drugs
| Otezla | 21 | $113,705 | $5,415 |
| Cosentyx Pen (2 Pens) | 13 | $90,266 | $6,944 |
| Fluorouracil | 51 | $4,983 | $98 |
| Clobetasol Propionate | 36 | $3,243 | $90 |
| Fluocinonide | 60 | $3,001 | $50 |
| Clindamycin Phosphate | 37 | $2,740 | $74 |
| Tretinoin | 21 | $2,552 | $122 |
| Metronidazole | 27 | $2,385 | $88 |
| Triamcinolone Acetonide | 100 | $2,080 | $21 |
| Ciclopirox | 79 | $1,761 | $22 |
| Doxycycline Hyclate | 14 | $1,447 | $103 |
| Nyamyc | 12 | $1,182 | $99 |
| Valacyclovir | 28 | $814 | $29 |
| Betamethasone Diprop Augmented | 28 | $551 | $20 |
| Ketoconazole | 15 | $540 | $36 |
| Ciclopirox | 20 | $519 | $26 |
| Cephalexin | 14 | $287 | $20 |
| Mirtazapine | 15 | $239 | $16 |
| Hydrocortisone | 30 | $166 | $6 |
| Mometasone Furoate | 15 | $155 | $10 |
| Mupirocin | 16 | $101 | $6 |
2021: 19 drugs
| Cosentyx Pen (2 Pens) | 13 | $81,404 | $6,262 |
| Otezla | 17 | $66,708 | $3,924 |
| Clobetasol Propionate | 50 | $5,402 | $108 |
| Fluorouracil | 46 | $3,794 | $82 |
| Clindamycin Phosphate | 39 | $3,299 | $85 |
| Fluocinonide | 41 | $2,152 | $52 |
| Tretinoin | 15 | $1,602 | $107 |
| Triamcinolone Acetonide | 64 | $1,445 | $23 |
| Metronidazole | 17 | $1,426 | $84 |
| Ciclopirox | 52 | $1,233 | $24 |
| Betamethasone Diprop Augmented | 21 | $779 | $37 |
| Nyamyc | 11 | $719 | $65 |
| Alclometasone Dipropionate | 19 | $586 | $31 |
| Mometasone Furoate | 21 | $393 | $19 |
| Minocycline | 16 | $311 | $19 |
| Valacyclovir | 16 | $212 | $13 |
| Mirtazapine | 11 | $163 | $15 |
| Hydrocortisone | 17 | $109 | $6 |
| Mupirocin | 11 | $58 | $5 |
2020: 19 drugs
| Dapsone | 12 | $3,802 | $317 |
| Doxycycline Hyclate | 13 | $3,628 | $279 |
| Clobetasol Propionate | 32 | $3,569 | $112 |
| Clindamycin Phosphate | 32 | $3,329 | $104 |
| Tretinoin | 22 | $3,179 | $144 |
| Fluorouracil | 26 | $2,977 | $115 |
| Metronidazole | 27 | $2,304 | $85 |
| Betamethasone Diprop Augmented | 26 | $2,074 | $80 |
| Fluocinonide | 46 | $1,863 | $41 |
| Triamcinolone Acetonide | 87 | $1,376 | $16 |
| Ciclopirox | 54 | $1,087 | $20 |
| Ciclopirox | 22 | $1,082 | $49 |
| Alclometasone Dipropionate | 20 | $568 | $28 |
| Valacyclovir | 23 | $484 | $21 |
| Nystatin | 14 | $480 | $34 |
| Mometasone Furoate | 31 | $474 | $15 |
| Mirtazapine | 12 | $263 | $22 |
| Hydrocortisone | 20 | $140 | $7 |
| Prednisone | 12 | $94 | $8 |
2019: 19 drugs
| Dapsone | 16 | $4,502 | $281 |
| Clindamycin Phosphate | 39 | $3,886 | $100 |
| Metronidazole | 30 | $3,744 | $125 |
| Doxycycline Hyclate | 18 | $2,625 | $146 |
| Fluorouracil | 23 | $2,551 | $111 |
| Azelaic Acid | 12 | $2,401 | $200 |
| Fluocinonide | 46 | $2,259 | $49 |
| Clobetasol Propionate | 25 | $2,189 | $88 |
| Betamethasone Diprop Augmented | 17 | $2,132 | $125 |
| Triamcinolone Acetonide | 75 | $835 | $11 |
| Alclometasone Dipropionate | 32 | $817 | $26 |
| Ciclopirox | 13 | $631 | $49 |
| Mometasone Furoate | 27 | $569 | $21 |
| Ciclopirox | 32 | $553 | $17 |
| Nystatin | 17 | $486 | $29 |
| Valacyclovir | 15 | $207 | $14 |
| Mirtazapine | 11 | $199 | $18 |
| Hydrocortisone | 14 | $130 | $9 |
| Mupirocin | 11 | $84 | $8 |
2018: 13 drugs
| Fluorouracil | 41 | $3,774 | $92 |
| Clobetasol Propionate | 24 | $3,244 | $135 |
| Metronidazole | 30 | $3,223 | $107 |
| Clindamycin Phosphate | 32 | $2,645 | $83 |
| Dapsone | 11 | $2,391 | $217 |
| Fluocinonide | 45 | $2,060 | $46 |
| Alclometasone Dipropionate | 40 | $1,400 | $35 |
| Triamcinolone Acetonide | 72 | $1,119 | $16 |
| Nystatin | 16 | $554 | $35 |
| Mometasone Furoate | 19 | $409 | $22 |
| Valacyclovir | 23 | $323 | $14 |
| Ciclopirox | 21 | $318 | $15 |
| Amoxicillin | 12 | $41 | $3 |
2017: 11 drugs
| Metronidazole | 27 | $3,792 | $140 |
| Clobetasol Propionate | 28 | $3,499 | $125 |
| Fluocinonide | 32 | $1,903 | $59 |
| Fluorouracil | 17 | $1,798 | $106 |
| Triamcinolone Acetonide | 48 | $1,036 | $22 |
| Clindamycin Phosphate | 14 | $1,011 | $72 |
| Alclometasone Dipropionate | 33 | $939 | $28 |
| Betamethasone Dipropionate | 13 | $843 | $65 |
| Ciclopirox | 23 | $414 | $18 |
| Valacyclovir | 13 | $174 | $13 |
| Mometasone Furoate | 11 | $107 | $10 |
2016: 6 drugs
| Clobetasol Propionate | 41 | $7,244 | $177 |
| Fluocinonide | 47 | $3,985 | $85 |
| Fluorouracil | 20 | $2,269 | $113 |
| Metronidazole | 13 | $2,164 | $166 |
| Triamcinolone Acetonide | 46 | $953 | $21 |
| Alclometasone Dipropionate | 12 | $345 | $29 |
2015: 7 drugs
| Clobetasol Propionate | 40 | $7,028 | $176 |
| Fluorouracil | 22 | $3,165 | $144 |
| Fluocinonide | 37 | $2,625 | $71 |
| Econazole Nitrate | 18 | $2,278 | $127 |
| Desonide | 26 | $2,243 | $86 |
| Triamcinolone Acetonide | 29 | $705 | $24 |
| Ketoconazole | 13 | $387 | $30 |
2014: 7 drugs
| Metronidazole | 14 | $2,686 | $192 |
| Fluorouracil | 15 | $2,431 | $162 |
| Clobetasol Propionate | 15 | $1,622 | $108 |
| Fluocinonide | 27 | $1,506 | $56 |
| Desonide | 21 | $1,312 | $62 |
| Triamcinolone Acetonide | 27 | $769 | $28 |
| Econazole Nitrate | 15 | $476 | $32 |
2013: 5 drugs
| Fluorouracil | 20 | $3,708 | $185 |
| Fluocinonide | 43 | $1,872 | $44 |
| Desonide | 20 | $1,516 | $76 |
| Clobetasol Propionate | 28 | $993 | $35 |
| Triamcinolone Acetonide | 28 | $821 | $29 |
Money from drug and device companies
$1,859 in 2025
| 2025 | 15 | 87 | None | $1,859 |
| 2024 | 12 | 32 | None | $834 |
| 2023 | 8 | 39 | None | $863 |
| 2022 | 7 | 11 | None | $258 |
| 2020 | 2 | 2 | None | $50 |
| 2019 | 1 | 1 | None | $23 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Galderma Laboratories L.P. | Nemluvio | $348 | 13 payments
|
| Arcutis Biotherapeutics | Zoryve | $230 | 15 payments
|
| Amgen | Otezla | $170 | 10 payments
|
| Janssen Biotech | Tremfya | $164 | 9 payments
|
| Abbvie | Skyrizi | $162 | 8 payments
|
| Regeneron Healthcare Solutions | Dupixent | $154 | 7 payments
|
See all 87 published payments
| Sun Pharmaceutical Industries | Meals · 2025-12-18 | Ilumya | $32 |
| Arcutis Biotherapeutics | Meals · 2025-12-16 | Zoryve | $19 |
| Galderma Laboratories L.P. | Meals · 2025-12-15 | Nemluvio | $37 |
| Genzyme | Meals · 2025-12-02 | Dupixent | $39 |
| Novartis Pharmaceuticals | Meals · 2025-12-01 | Rhapsido | $26 |
| Amgen | Meals · 2025-11-25 | Otezla | $34 |
| Arcutis Biotherapeutics | Meals · 2025-11-24 | Zoryve | $25 |
| Sun Pharmaceutical Industries | Meals · 2025-11-13 | Winlevi | $33 |
| Genzyme | Meals · 2025-10-23 | Dupixent | $34 |
| Regeneron Healthcare Solutions | Meals · 2025-10-16 | Dupixent | $27 |
| Galderma Laboratories L.P. | Meals · 2025-10-16 | Nemluvio | $15 |
| Galderma Laboratories L.P. | Meals · 2025-10-16 | Nemluvio | $7 |
| Novartis Pharmaceuticals | Meals · 2025-10-13 | Cosentyx | $19 |
| Amgen | Meals · 2025-10-09 | Otezla | $10 |
| Amgen | Meals · 2025-10-09 | Otezla | $2 |
| Amgen | Meals · 2025-10-09 | Otezla | $7 |
| Galderma Laboratories L.P. | Meals · 2025-10-09 | Nemluvio | $36 |
| Galderma Laboratories L.P. | Meals · 2025-10-09 | Nemluvio | $0 |
| Genzyme | Meals · 2025-10-07 | Dupixent | $30 |
| Regeneron Healthcare Solutions | Meals · 2025-09-30 | Dupixent | $19 |
| Galderma Laboratories L.P. | Meals · 2025-09-23 | Nemluvio | $26 |
| Ucb | Meals · 2025-09-18 | Bimzelx | $16 |
| Arcutis Biotherapeutics | Meals · 2025-09-15 | Zoryve | $13 |
| Janssen Biotech | Meals · 2025-09-04 | Tremfya | $4 |
| Janssen Biotech | Meals · 2025-09-04 | Tremfya | $22 |
| Janssen Biotech | Meals · 2025-09-04 | Tremfya | $0 |
| Galderma Laboratories L.P. | Meals · 2025-08-28 | Nemluvio | $38 |
| Arcutis Biotherapeutics | Meals · 2025-08-28 | Zoryve | $6 |
| Janssen Biotech | Meals · 2025-08-27 | Tremfya | $16 |
| Incyte | Meals · 2025-08-27 | Opzelura | $25 |
| Abbvie | Meals · 2025-08-21 | Skyrizi | $28 |
| Regeneron Healthcare Solutions | Meals · 2025-08-20 | Dupixent | $25 |
| Arcutis Biotherapeutics | Meals · 2025-08-18 | Zoryve | $5 |
| Janssen Biotech | Meals · 2025-08-13 | Tremfya | $32 |
| Lilly USA | Meals · 2025-08-07 | Taltz | $29 |
| Incyte | Meals · 2025-08-01 | Opzelura | $18 |
| Genzyme | Meals · 2025-07-31 | Dupixent | $25 |
| Organon | Meals · 2025-07-29 | Vtama | $18 |
| Janssen Biotech | Meals · 2025-07-24 | Tremfya | $2 |
| Janssen Biotech | Meals · 2025-07-23 | Tremfya | $26 |
| Abbvie | Meals · 2025-07-22 | Skyrizi | $5 |
| Abbvie | Meals · 2025-07-19 | Skyrizi | $17 |
| Incyte | Meals · 2025-07-15 | Opzelura | $29 |
| Amgen | Meals · 2025-07-14 | Otezla | $31 |
| Pfizer | Meals · 2025-07-14 | Cibinqo | $16 |
| Arcutis Biotherapeutics | Meals · 2025-07-14 | Zoryve | $7 |
| Regeneron Healthcare Solutions | Meals · 2025-07-11 | Dupixent | $20 |
| LEO Pharma | Meals · 2025-07-10 | Adbry | $24 |
| Organon | Meals · 2025-07-01 | Vtama | $23 |
| Arcutis Biotherapeutics | Meals · 2025-06-30 | Zoryve | $13 |
| Janssen Biotech | Meals · 2025-06-12 | Tremfya | $32 |
| Arcutis Biotherapeutics | Meals · 2025-06-12 | Zoryve | $10 |
| Amgen | Meals · 2025-05-30 | Otezla | $2 |
| Amgen | Meals · 2025-05-30 | Otezla | $30 |
| Galderma Laboratories L.P. | Meals · 2025-05-29 | Nemluvio | $34 |
| Regeneron Healthcare Solutions | Meals · 2025-05-27 | Dupixent | $21 |
| Galderma Laboratories L.P. | Meals · 2025-05-22 | Nemluvio | $29 |
| Abbvie | Meals · 2025-05-21 | Rinvoq | $12 |
| Abbvie | Meals · 2025-05-21 | Rinvoq | $17 |
| Arcutis Biotherapeutics | Meals · 2025-05-18 | Zoryve | $14 |
| Abbvie | Meals · 2025-05-07 | Skyrizi | $27 |
| Galderma Laboratories L.P. | Meals · 2025-05-07 | Nemluvio | $37 |
| Arcutis Biotherapeutics | Meals · 2025-05-05 | Zoryve | $33 |
| Arcutis Biotherapeutics | Meals · 2025-04-28 | Zoryve | $11 |
| Abbvie | Meals · 2025-04-21 | Skyrizi | $29 |
| Incyte | Meals · 2025-04-18 | Opzelura | $20 |
| Amgen | Meals · 2025-04-16 | Otezla | $1 |
| Amgen | Meals · 2025-04-16 | Otezla | $20 |
| Galderma Laboratories L.P. | Meals · 2025-04-15 | Nemluvio | $32 |
| Pfizer | Meals · 2025-04-08 | Cibinqo | $29 |
| Arcutis Biotherapeutics | Meals · 2025-03-27 | Zoryve | $25 |
| Regeneron Healthcare Solutions | Meals · 2025-03-21 | Dupixent | $18 |
| Galderma Laboratories L.P. | Meals · 2025-03-21 | Nemluvio | $31 |
| Lilly USA | Meals · 2025-03-18 | Ebglyss | $24 |
| Arcutis Biotherapeutics | Meals · 2025-03-17 | Zoryve | $2 |
| Ucb | Meals · 2025-02-28 | Bimzelx | $22 |
| Organon | Meals · 2025-02-28 | Vtama | $17 |
| Lilly USA | Meals · 2025-02-17 | Taltz | $29 |
| Regeneron Healthcare Solutions | Meals · 2025-02-06 | Dupixent | $24 |
| Arcutis Biotherapeutics | Meals · 2025-01-30 | Zoryve | $29 |
| Janssen Biotech | Meals · 2025-01-23 | Tremfya | $29 |
| Galderma Laboratories L.P. | Meals · 2025-01-22 | Nemluvio | $26 |
| Amgen | Meals · 2025-01-21 | Otezla | $33 |
| Arcutis Biotherapeutics | Meals · 2025-01-21 | Zoryve | $17 |
| Lilly USA | Meals · 2025-01-16 | Taltz | $24 |
| Organon | Meals · 2025-01-15 | Vtama | $33 |
| Abbvie | Meals · 2025-01-13 | Skyrizi | $27 |
See earlier years (2024, 2023, 2022, 2020, 2019)
2024: $834
| Amgen | Otezla | $267 | 10 payments
|
| E.R. Squibb & Sons L.L.C. | Sotyktu | $116 | 4 payments
|
| Lilly USA | Taltz | $96 | 3 payments
|
| Arcutis Biotherapeutics | Zoryve | $79 | 5 payments
|
| Janssen Biotech | Tremfya | $61 | 2 payments
|
| Regeneron Healthcare Solutions | Dupixent | $54 | 2 payments
|
| Abbvie | Skyrizi | $35 | 1 payment
|
| Dermavant Sciences | Vtama | $33 | 1 payment
|
| Sun Pharmaceutical Industries | Ilumya | $31 | 1 payment
|
| Incyte | Opzelura | $23 | 1 payment
|
| Galderma Laboratories L.P. | None | $21 | 1 payment
|
| Ucb | Bimzelx | $21 | 1 payment
|
2023: $863
| AbbVie | Skyrizi | $241 | 10 payments
|
| Amgen | Otezla | $206 | 11 payments
|
| Janssen Biotech | Tremfya | $100 | 4 payments
|
| LEO Pharma | Adbry | $80 | 3 payments
|
| Regeneron Healthcare Solutions | Dupixent | $64 | 3 payments
|
| Pfizer | Cibinqo | $57 | 3 payments
|
| Incyte | Opzelura | $57 | 3 payments
|
| E.R. Squibb & Sons L.L.C. | Sotyktu | $56 | 2 payments
|
2022: $258
| Regeneron Healthcare Solutions | Dupixent | $70 | 3 payments
|
| Incyte | Opzelura | $49 | 2 payments
|
| Abbvie | Rinvoq | $47 | 2 payments
|
| Pfizer | Cibinqo | $28 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Sotyktu | $24 | 1 payment
|
| LEO Pharma | Adbry | $23 | 1 payment
|
| Lilly USA | Taltz | $17 | 1 payment
|
2020: $50
| AbbVie | Skyrizi | $25 | 1 payment
|
| Regeneron Healthcare Solutions | Dupixent | $25 | 1 payment
|
2019: $23
| Sun Pharmaceutical Industries | Ilumya | $23 | 1 payment
|
Professional record
- NPI
- 1396966149
- Licence
- CA A88543California A88543: Current · expires 2028-02-29
- Trained
- Stanford University School of Medicine, 2003
- Group
- Stanford Health Care · Sutter Bay Medical Foundation
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207N00000X (207N00000X)
- Mailing address
- 325 Distel Cir, Los Altos, CA, 94022
- NPI first listed
- 2007-05-01
- NPI last updated
- 2024-04-16
- NPI record certified
- 2024-04-16
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 301 Industrial Rd, San Carlos, CA, 94070